IRIS Registry Analysis Shows Vision Gains With Aflibercept 8 mg

Data presented at AAO demonstrated longer injection intervals and improved visual outcomes in both treatment-naïve and treatment-experienced patients with wet AMD and DME.

By: Diana V. Do, MD

Retinal Physician October 21, 2025

Clinical Report: IRIS Registry Analysis Shows Vision Gains With Aflibercept 8 mg

Overview

The IRIS registry analysis demonstrated that aflibercept 8 mg leads to longer injection intervals and improved visual outcomes in both treatment-naïve and treatment-experienced patients with wet AMD and DME. Notably, treatment-naïve patients achieved a 12-week injection interval and significant vision gains.

Background

Aflibercept is a critical treatment for neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). Understanding the real-world effectiveness of aflibercept 8 mg is essential for optimizing treatment regimens and improving patient outcomes. The findings from the IRIS registry provide valuable insights into the potential benefits of this higher dose formulation.

Data Highlights

Patient Group	Injection Interval	Vision Gain (letters)
Treatment-Naïve AMD	12 weeks	4
Treatment-Naïve DME	12 weeks	5
Treatment-Experienced AMD	Additional 2 weeks	Maintained vision
Treatment-Experienced DME	Additional 2 weeks	Maintained vision

Key Findings

Aflibercept 8 mg allows treatment-naïve patients to achieve a 12-week injection interval after 6 months.
Treatment-naïve patients gained an average of 4 letters of vision in the AMD population and 5 letters in the DME population.
Treatment-experienced patients switching from aflibercept 2 mg to 8 mg extended their injection intervals by an additional 2 weeks.
Visual acuity was maintained in treatment-experienced patients after switching to aflibercept 8 mg.
The findings align with recent guidelines endorsing individualized treatment regimens for AMD and DME.

Clinical Implications

The results suggest that aflibercept 8 mg can effectively extend injection intervals while improving visual outcomes, which may reduce the treatment burden for patients. Clinicians should consider this option for both treatment-naïve and treatment-experienced patients to optimize management of wet AMD and DME.

Conclusion

The IRIS registry analysis highlights the efficacy of aflibercept 8 mg in achieving longer injection intervals and significant vision gains. These findings support its use in clinical practice for managing wet AMD and DME.

PentaVision

Retinal Physician